CITATION REPORT List of articles citing

Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimerts disease

DOI: 10.1007/bf02247426 Psychopharmacology, 1992, 108, 485-94.

Source: https://exaly.com/paper-pdf/23637634/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
408	A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. <i>Psychopharmacology</i> , 1992 , 108, 443-7	4.7	58
407	Effects of nicotine on human psychomotor performance. 1993 , 8, 155-184		58
406	Stimulant drugs and vigilance performance: a review. <i>Psychopharmacology</i> , 1993 , 111, 1-16	4.7	226
405	Effects of central nicotinic cholinergic receptor blockade produced by chlorisondamine on learning and memory performance in rats. 1993 , 60, 163-71		19
404	Clonidine-induced changes in the spectral distribution of heart rate variability correlate with performance on a test of sustained attention. 1994 , 8, 1-7		10
403	Age-related effects of the nicotinic antagonist mecamylamine on cognition and behavior. 1994 , 10, 93-	107	118
402	Effect of subcutaneous nicotine injections of EEG alpha frequency in non-smokers: a placebo-controlled pilot study. <i>Psychopharmacology</i> , 1994 , 115, 163-6	4.7	40
401	Nicotine increases sensory gating measured as inhibition of the acoustic startle reflex in rats. <i>Psychopharmacology</i> , 1994 , 114, 369-74	4.7	102
400	Nootropic effect of nicotine on carbon monoxide (CO)-induced delayed amnesia in mice. <i>Psychopharmacology</i> , 1994 , 116, 33-9	4.7	10
399	A low dose of subcutaneous nicotine improves information processing in non-smokers. <i>Psychopharmacology</i> , 1994 , 114, 628-34	4.7	121
398	Improvements in performance without nicotine withdrawal. <i>Psychopharmacology</i> , 1994 , 115, 539-42	4.7	78
397	Neurochemical mechanisms mediating the behavioral and cognitive effects of nicotine. 1994 , 31, 3-17		134
396	Intracerebroventricular nicotine and mecamylamine alter radial-arm maze performance in rats. 1994 , 31, 18-23		17
395	Effects of nicotinic agonists and antagonists on spatial working memory in normal adult and aged rats. 1994 , 31, 24-31		26
394	Nicotine interactions with dopamine agonists: Effects on working memory function. 1994 , 31, 32-37		25
393	Effect of flumazenil on the memory-enhancing properties of (Pinicotine in rodents. 1994 , 31, 38-44		4
392	Nicotine and tetrahydroaminoacradine: Evidence for improved attention in patients with dementia of the Alzheimer type. 1994 , 31, 80-88		44

(1995-1994)

391	Determination of enantiomeric purity of nicotine in pharmaceutical preparations by 13C-NMR in the presence of a chiral lanthanide shift reagent. 1994 , 12, 295-9	20
390	Are the cognitive-enhancing effects of nicotine in the rat with lesions to the forebrain cholinergic projection system mediated by an interaction with the noradrenergic system?. 1994 , 49, 511-21	65
389	Effect of nicotine, lobeline, and mecamylamine on sensory gating in the rat. 1994 , 49, 877-82	67
388	The reality of the beneficial effects of nicotine. 1994 , 89, 138-9; discussion 144-6	5
387	Interaction between 5-HT1A and nicotinic cholinergic receptors in the regulation of water maze navigation behavior. 1994 , 649, 174-80	25
386	Effects of ABT-418, a novel cholinergic channel ligand, on place learning in septal-lesioned rats. 1994 , 261, 217-22	57
385	Effects of smoking on memory for prose passages. 1994 , 56, 723-7	25
384	The pedunculopontine tegmental nucleus: a role in cognitive processes?. 1994 , 19, 298-318	134
383	Blockade of nicotinic responses by physostigmine, tacrine and other cholinesterase inhibitors in rat striatum. 1994 , 111, 695-702	45
382	Memory disorders: novel treatments, clinical perspective. 1994 , 55, 2189-94	10
381	Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: Effects on human cognitive functioning. 1994 , 31, 71-79	14
380	Cancer versus Alzheimer risks. Health is not moral. 1994 , 48, 273	
379	Human nicotinic receptorstheir role in aging and dementia. 1994 , 25, 93-7	102
378	Pharmacological manipulations of the alpha 2-noradrenergic system. Effects on cognition. 1994 , 5, 116-26	102
377	CNS Nicotinic Receptors. 1994 , 2, 216-233	41
376	Nicotine psychopharmacology: addiction, cognition and neuroadaptation. 1995 , 15, 47-72	99
375	Current pharmacological strategies in Alzheimer's disease. 1995 , 10, 633-646	1
374	Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron. 4.7 Psychopharmacology, 1995, 118, 82-92	197

373	Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats. <i>Psychopharmacology</i> , 1995 , 118, 195-205	4.7	80
372	Caffeine attenuates scopolamine-induced memory impairment in humans. <i>Psychopharmacology</i> , 1995 , 122, 158-68	4.7	105
371	Smoking, processing speed and attention in a choice reaction time task. <i>Psychopharmacology</i> , 1995 , 120, 209-12	4.7	37
370	Clonidine and diazepam have differential effects on tests of attention and learning. <i>Psychopharmacology</i> , 1995 , 120, 322-32	4.7	108
369	Phenyl pyrrolidine analogues as potent nicotinic acetylcholine receptor (nAChR) ligands. 1995 , 5, 991-99	96	22
368	Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. 1995 , 51, 509-14		168
367	Nicotine enhances the learning and memory of aged rats. 1995 , 52, 517-23		74
366	Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. 1995 , 674, 252-9		178
365	Effects of Nicotine on Biological Systems II. 1995 ,		6
364	Can an adjuvant treatment or a pharmacologic prevention be common to several diseases? The case of those associated to neuromediator defects. 1995 , 49, 161-7		
363	The pharmacotherapy of Alzheimer's disease based on the cholinergic hypothesis: an update. 1995 , 4, 349-56		88
362	Nicotinic receptors and cholinergic neurotransmission in the central nervous system. 1995 , 757, 73-83		16
361	Nicotine enhances Morris water maze performance of young and aged rats. 1995 , 16, 857-60		97
360	Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. 1995 , 56, 545-70		223
359	The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour. 1995 , 67, 165	-99	257
358	Quantitative Structure-Activity Relationships of Nicotinic Agonists. 1996 , 177-208		4
357	Cognitive performance effects of subcutaneous nicotine in smokers and never-smokers. <i>Psychopharmacology</i> , 1996 , 127, 31-8	4.7	207
356	Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. 1996 , 52, 58-73		132

355	Nicotine inhibits amyloid formation by the beta-peptide. 1996 , 35, 13568-78	214
354	Neuronal mechanisms mediating drug-induced cognition enhancement: cognitive activity as a necessary intervening variable. 1996 , 3, 329-43	42
353	Cognitive functions of the basal forebrain cholinergic system in monkeys: memory or attention?. 1996 , 75, 13-25	145
352	Depletion of serotonin, dopamine and noradrenaline in aged rats decreases the therapeutic effect of nicotine, but not of tetrahydroaminoacridine. 1996 , 308, 243-50	14
351	Nicotine blocks angiotensin II inhibition of LTP in the dentate gyrus. 1996 , 17, 1127-33	16
350	Treatment of Alzheimer's disease: future directions. 1996 , 165, 128-36	7
349	Effects of nicotine and amphetamine on latent inhibition in human subjects. <i>Psychopharmacology</i> , 1996 , 127, 164-73	138
348	Cognition enhancers in age-related cognitive decline. 1996 , 8, 245-74	53
347	Psychopharmacology of cognitive impairment in Parkinson's disease. 1996 , 363-380	
346	Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: A patch-clamp study. 1996 , 16, 7880-91	167
345	Does nicotine have beneficial effects in the treatment of certain diseases?. 1996 , 5, 1195-202	28
344	Are tobacco and alcohol use related to Alzheimer's disease? A critical assessment of the evidence and its implications. 1996 , 1, 237-54	30
343	Pharmacology of nicotine: addiction and therapeutics. 1996 , 36, 597-613	509
342	A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. 1996 , 34, 1085-95	469
341	New approach to drug therapy in Alzheimer's dementia Alfred Maelicke and Edson X. Albuquerque. 1996 , 1, 53-59	79
340	Cholinergic improvement of a naturally-occurring memory deficit in the young rat. 1996 , 707, 13-21	43
339	Increased regional cerebral glucose metabolism and semantic memory performance in Alzheimer's disease: a pilot double blind transdermal nicotine positron emission tomography study. 1996 , 6, 61-79	37
338	Nicotinic receptors in the brain. Molecular biology, function, and therapeutics. 1996 , 28, 3-11	37

337	A microdialysis study of the effects of the nicotinic agonist RJR-2403 on cortical release of acetylcholine and biogenic amines. 1996 , 21, 1181-6		38
336	Nicotine effects on adults with attention-deficit/hyperactivity disorder. <i>Psychopharmacology</i> , 1996 , 123, 55-63	4.7	352
335	Acute and chronic nicotine effects on working memory in aged rats. <i>Psychopharmacology</i> , 1996 , 123, 88-97	4.7	131
334	The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. <i>Psychopharmacology</i> , 1996 , 123, 239-49	4.7	82
333	Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation. <i>Psychopharmacology</i> , 1996 , 124, 323-31	4.7	74
332	Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders. 1996 , 72, 51-81		138
331	Nicotinic agonist and antagonist effects on memory. 1996 , 38, 188-195		23
330	Effects of nicotinic cholinergic agents on cognitive functioning in Alzheimer's and Parkinson's disease. 1996 , 38, 278-289		31
329	Long-term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex. 1996 , 39, 19-28		19
328	2-(Aryloxymethyl) azacyclic analogues as novel nicotinic acetylcholine receptor (nAChR) ligands. 1996 , 6, 2283-2288		26
327	Neuropharmacology. Psychoactive smoke. 1996 , 379, 677-8		30
326	Epidemiology of the dementias: recent developments and new approaches. 1996 , 60, 478-88		55
325	The pharmacology of (-)-nicotine and novel cholinergic channel modulators. 1997 , 37, 153-214		99
324	Do pulmonary function and smoking behavior predict cognitive function? findings from a british sample. 1997 , 12, 265-275		15
323	Effect of haloperidol on nicotine-induced enhancement of vigilance in human subjects. 1997 , 11, 253-7		9
322	1 Pharmacology of Alzheimer's Disease. 1997 , 34, 1-67		6
321	Enhanced release of secreted form of Alzheimer's amyloid precursor protein from PC12 cells by nicotine. 1997 , 52, 430-6		68
320	Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease. 1997 , 8, 1845-9		15

319	Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. 1997 , 11, 206-28	200
318	Pathological mutations of nicotinic receptors and nicotine-based therapies for brain disorders. 1997 , 7, 674-82	91
317	Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers. 1997 , 83, 7-14	55
316	Smoking and attention: a review and reformulation of the stimulus-filter hypothesis. 1997 , 17, 451-78	107
315	Human neuronal nicotinic receptors. 1997 , 53, 199-237	361
314	The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. 1997 , 92, 1773-1782	41
313	Pharmacological Characterization of RJR-2403: A Nicotinic Agonist with Potential Therapeutic Benefit in the Treatment of Alzheimer's Disease. 1997 , 3, 325-345	6
312	Acetylcholine, aging, and Alzheimer's disease. 1997 , 56, 687-96	277
311	Nicotinic acetylcholine receptor (nACh-R) agonist-induced changes in brain monoamine turnover in mice. <i>Psychopharmacology</i> , 1997 , 129, 225-32	21
310	Improvement in accuracy of delayed recall in aged and non-aged, mature monkeys after intramuscular or transdermal administration of the CNS nicotinic receptor agonist ABT-418. 4.7 Psychopharmacology, 1997, 130, 276-84	35
309	Effects of altering brain cholinergic activity on covert orienting of attention: comparison of monkey and human performance. <i>Psychopharmacology</i> , 1997 , 132, 324-34	153
308	Identification of novel (isoxazole)methylene-1-azabicyclic compounds with high affinity for the central nicotinic cholinergic receptor. 1997 , 7, 1963-1968	9
307	Smoking and cognitive decline. 1997 , 12, 467-480	6
306	Cholinergic channel activator, ABT-418, enhances delayed-response accuracy in rats. 1997 , 40, 304-312	11
305	The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems. 1998 , 23, 787-94	78
304	The effects of nicotine on spatial and non-spatial expectancies in a covert orienting task. 1998 , 36, 1103-14	64
303	Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brainan in vivo microdialysis study. 1998 , 351, 181-8	60
302	Allosteric nicotinic receptors, human pathologies. 1998 , 92, 63-74	72

301	Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. 1998 , 43, 311-7		55
300	Critical flicker fusion threshold: a useful research tool in patients with Alzheimer's disease. 1998 , 13, 337-355		11
299	Separation of nicotine and nornicotine enantiomers via normal phase HPLC on derivatized cellulose chiral stationary phases. 1998 , 10, 364-369		38
298	Enantiomeric composition of nicotine in smokeless tobacco, medicinal products, and commercial reagents. 1998 , 10, 587-591		55
297	Scopolamine model of delirium in rats and reversal of the performance impairment by aniracetam. 1998 , 43, 85-97		17
296	Antiamnesic activity of the nicotinic agonist DBO-83 in mice. 1998 , 45, 45-51		2
295	Evaluation of the information processing and mood effects of a transdermal nicotine patch. <i>Psychopharmacology</i> , 1998 , 135, 305-10	4.7	107
294	Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. <i>Psychopharmacology</i> , 1998 , 136, 50-8	4.7	81
293	Nicotinic acetylcholine involvement in cognitive function in animals. <i>Psychopharmacology</i> , 1998 , 138, 217-30	4.7	595
292	Nicotine enhances sustained attention in the rat under specific task conditions. <i>Psychopharmacology</i> , 1998 , 138, 266-74	4.7	165
291	Transdermal nicotine effects on attention. <i>Psychopharmacology</i> , 1998 , 140, 135-41	4.7	281
290	Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. 1998 , 55, 343-61		684
289	Expression of the alpha3 nicotinic receptor subunit mRNA in aging and Alzheimer's disease. 1998 , 63, 72-8		46
288	Age-related differences in distractibility and response to methylphenidate in monkeys. 1998 , 8, 164-72		28
287	Treatment of Cognitive Impairment in Alzheimer's Disease. 1998 , 28, 261-266		9
286	Nicotinic cholinergic receptor deficits in Alzheimer's disease: where's the smoke?. 1999 , 1, 221-30		5
285	Tobacco smoking and memory scanning: behavioral and event-related potential effects. 1999 , 1, 233-40)	11
284	Neuronal Plasticity: Building a Bridge from the Laboratory to the Clinic. <i>Research and Perspectives in Neurosciences</i> , 1999 ,		5

(2000-1999)

283	performance. 1999 , 18, 123-30	25
282	Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. 1999 , 11, 2551-65	135
281	Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. <i>Psychopharmacology</i> , 1999 , 142, 334-42	124
2 80	Four-week nicotine skin patch treatment effects on cognitive performance in Alzheimer's disease. *Psychopharmacology*, 1999 , 143, 158-65 4-7	221
279	Enhancement of sustained attention performance by the nicotinic acetylcholine receptor agonist ABT-418 in intact but not basal forebrain-lesioned rats. <i>Psychopharmacology</i> , 1999 , 144, 175-82	112
278	Human and animal studies of schizophrenia-related gating deficits. 1999 , 1, 31-40	98
277	Acute and chronic nicotine exposure differentially facilitate the induction of LTP. 1999, 846, 137-43	178
276	Separate and combined effects of scopolamine and mecamylamine on human event-related brain potentials. 1999 , 14, 307-317	7
275	Comparative studies of epibatidine derivatives [18F]NFEP and [18F]N-methyl-NFEP: kinetics, nicotine effect, and toxicity. 1999 , 26, 139-48	48
274	In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. 1999 , 1454, 143-52	83
273	Ventral hippocampal ibotenic acid lesions block chronic nicotine-induced spatial working memory improvement in rats. 1999 , 7, 405-10	43
272	Nicotine enhancement of contextual fear conditioning. 1999 , 102, 31-9	140
271	Subunit and region-specific decreases in nicotinic acetylcholine receptor mRNA in the aged rat brain. 1999 , 20, 37-46	20
270	Reappraising neurotransmitter-based strategies. 1999 , 9 Suppl 2, S53-9	10
269	Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. 2000 , 31, 91-101	
268	Cognitive impairment without dementia in older people: prevalence, vascular risk factors, impact on disability. The Italian Longitudinal Study on Aging. 2000 , 48, 775-82	197
267	A unifying hypothesis of Alzheimer's disease. III. Risk factors. 2000 , 15, 1-70	32
266	Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. 2000 , 176, 27-33	36

265	Attention as a target of intoxication: insights and methods from studies of drug abuse. 2000 , 22, 487-502	31
264	Nicotine impairs spatial working memory while leaving spatial attention intact. 2000 , 22, 200-9	50
263	Effects of acute nicotine on several operant behaviors in rats. 2000 , 65, 247-54	47
262	Nicotine enhances stimulus detection performance of middle- and old-aged rats: a longitudinal study. 2000 , 65, 665-70	29
261	Nicotine, brain nicotinic receptors, and neuropsychiatric disorders. 2000, 31, 131-44	140
260	Nicotinic systems in central nervous systems disease: degenerative disorders and beyond. 2000 , 74, 91-101	62
259	Development of nicotinic drug therapy for cognitive disorders. 2000 , 393, 141-6	127
258	Nicotine in an animal model of attention. 2000 , 393, 147-54	109
257	TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. 2000, 409, 45-55	34
256	Cholinergic neurotransmission influences covert orientation of visuospatial attention in the rat. *Psychopharmacology*, 2000 , 150, 112-6 4-7	82
255	Non-stimulant treatments for ADHD. 2000 , 9 Suppl 1, I51-9	33
254	Nicotine enhances the biosynthesis and secretion of transthyretin from the choroid plexus in rats: implications for beta-amyloid formation. 2000 , 20, 1318-23	50
253	Local infusion of scopolamine into intraparietal cortex slows covert orienting in rhesus monkeys. 2000 , 83, 1536-49	147
252	Pharmacotherapy of Attention Deficit Hyperactivity Disorder. 2000 , 9, 77-97	73
251	Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior. 2000 , 57, 193-202	18
250	Biological Aspects of the Link between Smoking and Depression. 2000 , 8, 99-110	97
249	A Critique of Nicotine Addiction. 2000 ,	25
248	On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. 2000 , 163, 495-529	567

(2001-2000)

247	Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. 2000, 98, 79-87	136
246	Nicotine patches improve mood and response speed in a lexical decision task. 2000 , 25, 549-57	13
245	Direct and indirect effects of nicotine/smoking on cognition in humans. 2000 , 25, 29-43	45
244	Central nicotinic receptors, neurotrophic factors and neuroprotection. 2000 , 113, 21-34	185
243	Nicotinic treatment for degenerative neuropsychiatric disorders such as Alzheimer's disease and Parkinson's disease. 2000 , 113, 121-9	70
242	Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. 2000 , 113, 207-15	62
241	Effect of subtype selective nicotinic compounds on attention as assessed by the five-choice serial reaction time task. 2000 , 117, 197-208	219
240	Neuronal nicotinic receptors in the human brain. 2000 , 61, 75-111	641
239	Nicotinic receptors in human brain: topography and pathology. 2000 , 20, 281-98	143
238	Ventral hippocampal alpha4beta2 nicotinic receptors and chronic nicotine effects on memory. 2000 , 39, 2770-8	82
237	Medicinal Plant Extracts for the Treatment of Dementia. 2000 , 13, 201-213	47
236	Brain imaging and the effects of caffeine and nicotine. 2000 , 32, 592-9	40
235	Adjunctive donepezil in attention deficit hyperactivity disorder youth: case series. 2000, 10, 217-22	41
234	Treatment of Alzheimer's disease: rationale and strategies. 2000 , 18, 807-28	30
233	Nicotinic treatment of Alzheimer's disease. 2001 , 49, 268-78	109
232	Cognitive effects of nicotine. 2001 , 49, 258-67	468
231	Nicotinic receptor-mediated protection against beta-amyloid neurotoxicity. 2001, 49, 233-9	90
230	Nicotine and its interaction with beta-amyloid protein: a short review. 2001 , 49, 221-32	42

229	Effects of nicotine on APP secretion and Abeta- or CT(105)-induced toxicity. 2001, 49, 240-7	33
228	Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. 2001 , 49, 200-10	273
227	Cholinergic Treatments of Alzheimer's Disease. 2001 , 475-486	3
226	Nicotine for Alzheimer's disease. 2001 ,	7
225	Acute effect of nicotine on non-smokers: III. LLRs and EEGs. 2001 , 160, 99-110	20
224	Association analysis of the partially duplicated alpha7 nicotinic acetylcholine receptor genetic variant and Alzheimer's disease. 2001 , 12, 301-4	11
223	Effects of chronic nicotine and methylphenidate in adults with attention deficit/hyperactivity disorder. 2001 , 9, 83-90	134
222	Effects of transdermal nicotine on attention and memory in healthy elderly non-smokers. *Psychopharmacology*, 2001 , 159, 83-8 4-7	47
221	Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. 2000 , 74, 237-43	214
220	Influence of cigarette smoking on prepulse inhibition of the acoustic startle response in schizophrenia. 2001 , 16, 321-326	104
219	Which Aspects of ADHD Are Associated with Tobacco Use in Early Adolescence?. 2001, 42, 493-502	124
218	Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. 2001 , 92, 89-108	178
217	Different pharmacokinetics of nicotine following intravenous administration of nicotine base and nicotine hydrogen tartarate in rats. 2001 , 77, 183-90	22
216	Ventral hippocampal alpha 7 nicotinic receptor blockade and chronic nicotine effects on memory performance in the radial-arm maze. 2001 , 70, 467-74	78
215	Acute and chronic nicotine exposure reverse age-related declines in the induction of long-term potentiation in the rat hippocampus. 2001 , 894, 347-53	53
214	A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. 2002 , 5, 189-202	122
213	Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. 2001 , 3, 17-24	1
212	Nicotine enhances latent inhibition and ameliorates ethanol-induced deficits in latent inhibition. 2001 , 3, 17-24	52

211	Functional mitochondria are required for amyloid beta-mediated neurotoxicity. 2001, 15, 1439-41	180
210	Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. 2001 , 56, 1154-66	652
209	Nicotine effects on alertness and spatial attention in non-smokers. 2002 , 4, 185-94	48
208	Nicotine's effect on neural and cognitive functioning in an aging population. 2002 , 6, 129-38	15
207	Effects of 10 mg and 15 mg oral procyclidine on critical flicker fusion threshold and cardiac functioning in healthy human subjects. 2002 , 16, 183-7	7
206	Effects of a low dose of transdermal nicotine on information processing. 2002 , 4, 275-85	15
205	A pilot controlled trial of transdermal nicotine in the treatment of attention deficit hyperactivity disorder. 2002 , 3, 150-5	38
204	Effects of (+/-)-4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a selective ligand for nicotinic acetylcholine receptors, in tests of visual attention and distractibility in rats and monkeys. 2002 , 301, 284-92	58
203	Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. 2002 , 1, 5-20	45
202	Non-stimulant treatment for Attention-Deficit/Hyperactivity Disorder. 2002 , 6 Suppl 1, S109-19	38
201	Open field habituation learning is improved by nicotine and attenuated by mecamylamine administered posttrial into the nucleus accumbens. 2002 , 77, 277-90	32
200	Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention. 2002 , 16, 485-500	7
199	Cognitive mechanisms of nicotine on visual attention. 2002 , 36, 539-48	274
198	Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. 2002, 109, 757-65	183
197	Immunohistochemical localisation of nicotinic acetylcholine receptor subunits in human cerebellum. 2002 , 113, 493-507	72
196	Differential roles for nicotinic and muscarinic cholinergic receptors in sustained visuo-spatial attention? A study using a 5-arm maze protocol in mice. 2002 , 128, 91-102	19
195	Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. 2002 , 26, 913-8	34
194	Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. 2002 , 68, 209-45	527

193	Attention-deficit/hyperactivity disorder. 2002, 230-264	Ο
192	The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. 2002 , 441, 115-25	75
191	Nicotine compensates for the loss of cholinergic function to enhance long-term potentiation induction. 2002 , 946, 148-52	37
190	Nicotine-induced attentional enhancement in rats: effects of chronic exposure to nicotine. 2002 , 27, 712-22	62
189	Persistence of nicotinic agonist RJR 2403-induced working memory improvement in rats. 2002 , 55, 97-103	27
188	Commentary on: "Effects of scopolamine and nicotine on human rapid information processing performance." Psychopharmacology (1984) 82:147-150. Nicotine improves information processing: 4.7 saying the unthinkable. <i>Psychopharmacology</i> , 2002 , 162, 345-8	3
187	The 5-choice serial reaction time task: behavioural pharmacology and functional neurochemistry. *Psychopharmacology*, 2002 , 163, 362-80 4-7	997
186	Disturbances of consciousness in dementia with Lewy bodies associated with alteration in nicotinic receptor binding in the temporal cortex. 2002 , 11, 461-74	55
185	Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. 2002 , 97, 15-28	102
184	Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus. 1999 , 73, 1590-7	195
183	Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease. 1999 , 73, 1635-40	155
182	Nicotine produces a within-subject enhancement of contextual fear conditioning in C57BL/6 mice independent of sex. 2003 , 38, 124-32	40
181	Effects of histamine and cholinergic systems on memory retention of passive avoidance learning in rats. 2003 , 465, 91-6	52
180	Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications. 2003 , 23, 393-426	102
179	Multiple neuronal networks mediate sustained attention. 2003 , 15, 1028-38	253
178	Drug therapy for adults with attention-deficit hyperactivity disorder. 2003 , 63, 2395-411	63
177	Cognitive effects of nicotine in humans: an fMRI study. 2003 , 19, 1002-13	205
176	Role of central cholinergic receptor sub-types in spatial working memory: a five-arm maze task in mice provides evidence for a functional role of nicotinic receptors in mediating trace access processes. 2003 , 120, 1049-59	18

(2004-2003)

175	Protein and mRNA levels of nicotinic receptors in brain of tobacco using controls and patients with Alzheimer's disease. 2003 , 122, 515-20	50
174	Mecamylamine reversal by nicotine and by a partial alpha7 nicotinic acetylcholine receptor agonist (GTS-21) in rabbits tested with delay eyeblink classical conditioning. 2003 , 143, 159-67	42
173	Nicotine enhances contextual fear conditioning in C57BL/6J mice at 1 and 7 days post-training. 2003 , 80, 147-57	111
172	Complementary and alternative medicines in the treatment of dementia: an evidence-based review. 2003 , 20, 981-98	24
171	A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. 2003 , 20, 777-89	139
170	Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. 2003 , 28, 1235-46	63
169	Reversal of a vigilance decrement in the aged rat by subtype-selective nicotinic ligands. 2003, 28, 880-7	64
168	Visuospatial dysfunction in the neurodegenerative diseases. 2003 , 8, e428-36	32
167	Human functional neuroimaging in nicotine and tobacco research: basics, background, and beyond. 2004 , 6, 941-59	39
166	Nicotine improves learning and memory in rats: morphological evidence for acetylcholine involvement. 2004 , 114, 1163-79	14
165	Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. 2004 , 18, 457-74	180
164	Cortical cholinergic function and deficits in visual attentional performance in rats following 192 IgG-saporin-induced lesions of the medial prefrontal cortex. 2004 , 14, 922-32	137
163	Switching from donepezil or rivastigmine to galantamine in clinical practice. 2004 , 52, 1965	9
162	Non-stimulant medications in the treatment of ADHD. 2004 , 13 Suppl 1, I102-16	85
161	Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. <i>Psychopharmacology</i> , 2004 , 171, 465-71	86
160	Effects of nicotine and mecamylamine on cognition in rhesus monkeys. <i>Psychopharmacology</i> , 2004 , 4·7	42
159	Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. <i>Psychopharmacology</i> , 2004 , 174, 86-98	101
158	Long-Term Outcomes of Galantamine Treatment in Patients With Alzheimer Disease. 2004 , 12, 473-482	26

157	Effects of cholinergic enhancement on visual stimulation, spatial attention, and spatial working memory. 2004 , 41, 969-82	159
156	Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders. 2004 , 18, 457-474	193
155	Pathogenesis of Alzheimer Disease: Metabolic Factors. 2004 , 303-353	
154	Nicotine-induced switch in the nicotinic cholinergic mechanisms of facilitation of long-term potentiation induction. 2005 , 22, 845-60	54
153	Acute effects of nicotine on attention and response inhibition. 2005 , 82, 539-48	50
152	An open trial of adjunctive donepezil in attention-deficit/hyperactivity disorder. 2005 , 15, 947-55	22
151	Acute effect of nicotine on auditory gating in smokers and non-smokers. 2005, 202, 114-28	55
150	Role of alpha7-nicotinic acetylcholine receptors in tetanic stimulation-induced gamma oscillations in rat hippocampal slices. 2005 , 48, 869-80	60
149	Psicofarmacologa de la nicotina y conducta adictiva. 2005 , 7, 137-152	3
148	Nicotine and cognitive efficiency in alcoholics and illicit stimulant abusers: implications of smoking cessation for substance users in treatment. 2006 , 41, 265-81	21
147	Effect of vitamin E on memory retention in rats: possible involvement of cholinergic system. 2006 , 16, 101-6	25
146	Transdermal treatment options for neurological disorders: impact on the elderly. 2006 , 23, 357-75	48
145	Tobacco use, alcohol dependence, and cognitive performance. 2006 , 133, 375-88	28
144	Preclinical research into cognition enhancers. 2006 , 27, 602-8	47
143	A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. 2006 , 26, 163-6	25
142	Effects of low dose nicotine on attention and incidental learning in smokers and never-smokers. 2006 , 5, 1	
141	Nicotine exposure in vivo induces long-lasting enhancement of NMDA receptor-mediated currents in the hippocampus. 2006 , 23, 1819-28	48
140	Nicotine withdrawal suppresses nicotinic modulation of long-term potentiation induction in the hippocampal CA1 region. 2006 , 24, 2903-16	22

(2007-2006)

139	Chronic nicotine-induced switch in Src-family kinase signaling for long-term potentiation induction in hippocampal CA1 pyramidal cells. 2006 , 24, 3271-84		11
138	TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. 2004 , 10, 147-66		91
137	Nicotine-induced enhancement of synaptic plasticity at CA3-CA1 synapses requires GABAergic interneurons in adult anti-NGF mice. 2006 , 576, 361-77		29
136	Nicotine exposure does not alter plasma to brain choline transfer. 2006 , 31, 503-8		5
135	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. <i>Psychopharmacology</i> , 2006 , 188, 509-20	4.7	109
134	The role of nicotinic acetylcholine receptors in Alzheimer's disease. 2006 , 99, 172-9		100
133	Thalamic nicotinic receptors implicated in disturbed consciousness in dementia with Lewy bodies. 2006 , 21, 50-6		52
132	Effects of Salvia officinalis L. (sage) leaves on memory retention and its interaction with the cholinergic system in rats. 2006 , 22, 321-6		52
131	Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series. 2006 , 9, 543-9		24
130	Apolipoprotein E-derived peptides block alpha7 neuronal nicotinic acetylcholine receptors expressed in xenopus oocytes. 2006 , 316, 835-42		25
129	Beyond methylphenidate: nonstimulant medications for youth with ADHD. 2007 , 11, 341-50		18
128	Onde P50 dans la schizophrfiie. 2007 , 4, 1-11		2
127	Cognition Enhancers. 2007 , 241-283		5
126	Fear-potentiated startle to threat, and prepulse inhibition among young adult nonsmokers, abstinent smokers, and nonabstinent smokers. 2007 , 62, 1155-61		22
125	Smoking-responsive juvenile-onset Parkinsonism. 2007 , 22, 115-9		21
124	Increased binding potential of [(11)C]raclopride during unilateral continuous microinjection of nicotine in rat striatum observed by positron emission tomography. 2007 , 61, 943-50		1
123	Nicotine gates long-term potentiation in the hippocampal CA1 region via the activation of alpha2* nicotinic ACh receptors. 2007 , 25, 2666-81		73
122	Nicotine's effects on attentional efficiency in alcoholics. 2007 , 31, 2083-91		24

121	Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. 2007 , 74, 1212-23	117
120	Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. 2007 , 74, 1192-201	123
119	Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: a 2-[18F]fluoro-A-85380 PET study. 2008 , 90, 404-12	52
118	Choline pivaloyl ester enhances brain expression of both nerve growth factor and high-affinity receptor TrkA, and reverses memory and cognitive deficits, in rats with excitotoxic lesion of nucleus basalis magnocellularis. 2008 , 190, 22-32	6
117	Cholinergic components of frontal lobe function and dysfunction. 2008, 88, 1-30	2
116	Nicotine aerosol generation from thermally reversible zinc halide complexes using the Staccato system. 2008 , 34, 936-42	8
115	Perspectives of Alzheimer's disease treatments. 2008 , 89, 273-90	1
114	Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. 2008 , 22, 30-8	24
113	Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB. 1993 , 149, 29-35	25
112	Cholinergic therapy in dementia. 1993 , 149, 42-5	27
111	nAChR agonist-induced cognition enhancement: integration of cognitive and neuronal mechanisms. 2009 , 78, 658-67	103
110	Nicotine self-medication of cognitive-attentional processing. 2009 , 14, 32-42	118
109	Effects of sensory modality on cerebral blood flow velocity during vigilance. 2009, 461, 207-11	82
108	Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders. 2009 , 10, 2709-21	73
107	Modifiable lifestyle risk factors for Alzheimer's disease. 2010 , 20, 803-11	50
106	The dopaminergic basis of cognitive and motor performance in Alzheimer's disease. 2010 , 37, 477-82	21
105	Acute nicotine treatment prevents REM sleep deprivation-induced learning and memory impairment in rat. 2011 , 21, 899-909	64
104	Assessing cognitive function in clinical trials of schizophrenia. 2010 , 34, 1161-77	124

103	Cigarette smoking and cognitive impairment: a 10-year cohort study in Taiwan. 2010 , 51, 143-8	34
102	Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. 2010 , 4, 349-71	79
101	ABT-594 improves performance in the 5-choice serial reaction time task under conditions of increased difficulty, sub-chronic dosing, and in poorly-performing subjects. 2010 , 95, 146-57	19
100	Ethanol extract and saponin of Platycodon grandiflorum ameliorate scopolamine-induced amnesia in mice. 2010 , 13, 584-8	10
99	Post-learning REM sleep deprivation impairs long-term memory: reversal by acute nicotine treatment. 2011 , 499, 28-31	50
98	Galantamine improves sustained attention in chronic cocaine users. 2011 , 19, 11-9	34
97	PASS assisted prediction and pharmacological evaluation of novel nicotinic analogs for nootropic activity in mice. 2011 , 662, 22-30	55
96	Cholinergic receptor subtypes and their role in cognition, emotion, and vigilance control: an overview of preclinical and clinical findings. <i>Psychopharmacology</i> , 2011 , 215, 205-29	69
95	Prompt but inefficient: nicotine differentially modulates discrete components of attention. *Psychopharmacology*, 2011 , 218, 667-80 4-7	76
94	Tobacco use and dementia: evidence from the 1066 dementia population-based surveys in Latin America, China and India. 2011 , 26, 1177-85	12
93	Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). 2011 , 31, 3500-7	118
92	Smoking, death, and Alzheimer disease: a case of competing risks. 2012 , 26, 300-6	47
91	Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial. 2012 , 78, 91-101	140
90	Cholinergic modulation of response gain in the primary visual cortex of the macaque. 2012 , 107, 283-91	56
89	Relations among acute and chronic nicotine administration, short-term memory, and tactics of data analysis. 2012 , 98, 155-67	3
88	Nicotinic receptor activation in perirhinal cortex and hippocampus enhances object memory in rats. 2012 , 62, 2096-105	36
87	Nicotine evoked improvement in learning and memory is mediated through NPY Y1 receptors in rat model of Alzheimer's disease. 2012 , 33, 317-28	39
86	Endogenously released ACh and exogenous nicotine differentially facilitate long-term potentiation in the hippocampal CA1 region of mice. 2012 , 35, 1381-95	35

85	Nicotine uses neuron-glia communication to enhance hippocampal synaptic transmission and long-term memory. 2012 , 7, e49998		24
84	Nicotine: specific role in angiogenesis, proliferation and apoptosis. 2012 , 42, 68-89		85
83	The nicotinic acetylcholine receptor: smoking and Alzheimer's disease revisited. 2012, 4, 169-80		6
82	Does coffee enriched with chlorogenic acids improve mood and cognition after acute administration in healthy elderly? A pilot study. <i>Psychopharmacology</i> , 2012 , 219, 737-49	4.7	57
81	Cognition as a therapeutic target in late-life depression: potential for nicotinic therapeutics. 2013 , 86, 1133-44		13
80	Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. 2013 , 4, 1495		71
79	Radiosynthesis and first evaluation in mice of [(18)F]NS14490 for molecular imaging of II nicotinic acetylcholine receptors. 2013 , 21, 2635-42		27
78	Prevention of Brain Disorders by Nicotine. 2013 , 1469-1501		
77	Leveraging the cortical cholinergic system to enhance attention. 2013 , 64, 294-304		52
76	Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status. 2013 , 27, 1007-14		8
75	Role of 🛭 - and 🖺 - nAChRs in the neuroprotective effect of nicotine in stress-induced impairment of hippocampus-dependent memory. 2013 , 16, 1105-13		18
74	Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice. 2014 , 6, 162		23
73	The functional therapeutic chemical classification system. 2014 , 30, 876-83		5
72	Endogenous ACh suppresses LTD induction and nicotine relieves the suppression via different nicotinic ACh receptor subtypes in the mouse hippocampus. 2014 , 111, 62-8		8
71	The effects of galantamine treatment on attention and its relationship with cognition and activities of daily living in patients with mild to moderate Alzheimer's disease. 2015 , 11, 66-72		5
70	Functional Activation during the Rapid Visual Information Processing Task in a Middle Aged Cohort: An fMRI Study. 2015 , 10, e0138994		23
69	Animal paradigms to assess cognition with translation to humans. 2015 , 228, 27-57		16
68	The effect of oppositional parietal transcranial direct current stimulation on lateralized brain functions. 2015 , 42, 2904-14		19

67	Traumatic Brain Injury. 2015 , 32, 1429-40	53
66	Nicotinic receptors and attention. 2015 , 23, 103-35	25
65	The Neurobiology and Genetics of Nicotine and Tobacco. 2015,	4
64	The effect of self-regulated caffeine use on cognition in young adults. 2015 , 30, 123-30	6
63	Effect of the Nicotinic 🗓 receptor Partial Agonist Varenicline on Non-invasive Brain Stimulation-Induced Neuroplasticity in the Human Motor Cortex. 2015 , 25, 3249-59	23
62	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. 2016 , 7, 88	20
61	Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse. 2016 , 81, 295-305	8
60	Radio synthesis and in vivo evaluation of two 🛭 nAChRs radioligands: [1251]CAIPE and [1251]IPPU. 2016 , 307, 1345-1351	3
59	Effects of socio-demographic variables on performance on the Cambridge neuropsychological automated tests for the assessment of dementia and Portuguese norms for older adults living in retirement homes. 2016 , 30, 284-317	3
58	Effects of the nicotinic agonist varenicline on the performance of tasks of cognition in aged and middle-aged rhesus and pigtail monkeys. <i>Psychopharmacology</i> , 2016 , 233, 761-71	16
57	Validation of the human odor span task: effects of nicotine. <i>Psychopharmacology</i> , 2017 , 234, 2871-2882 4.7	5
56	Enantiomeric composition of nicotine in tobacco leaf, cigarette, smokeless tobacco, and e-liquid by normal phase high-performance liquid chromatography. 2018 , 30, 923-931	7
55	Introduction. 2018, xix-xxi	
54	Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases - Pages 109-136. 2018 , 109-136	
53	Using event-related fMRI to examine sustained attention processes and effects of APOE 4 in young adults. 2018 , 13, e0198312	2
52	Atomoxetine improves memory and other components of executive function in young-adult rats and aged rhesus monkeys. 2019 , 155, 65-75	14
51	Short-term auricular electrical stimulation rapidly elevated cortical blood flow and promoted the expression of nicotinic acetylcholine receptor 4 in the 2 vessel occlusion rats model. 2019 , 26, 36	6
50	Natural Compounds for Alzheimer's Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. 2019 , 20,	85

49	Healthy Subjects With Extreme Patterns of Performance Differ in Functional Network Topology and Benefits From Nicotine. 2019 , 13, 83	:	1
48	APOE genotype influences P3b amplitude and response to smoking abstinence in young adults. <i>Psychopharmacology</i> , 2021 , 238, 1171-1181	4.7	
47	Preventing dementia? Interventional approaches in mild cognitive impairment. 2021, 122, 143-164	-	12
46	Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends. 2021 , 139, 111634	,	O
45	Nicotine Enhances Object Recognition Memory via Stimulating 🗓 and 🖟 Nicotinic Acetylcholine Receptors in the Medial Prefrontal Cortex of Mice. 2021 , 44, 1007-1013	-	1
44	Ultrasound-triggered nicotine release from nicotine-loaded cellulose hydrogel. 2021 , 78, 105710	,	O
43	Multiple motivational forces contribute to nicotine dependence. 2009 , 55, 65-89	:	13
42	Nicotinic Receptors in the Central Nervous System. 1996 , 147-168	:	1
41	Development of Nicotinic Agonists for the Treatment of Alzheimer Disease. 1994 , 186-190		4
40	The Subunit Specific Effects of Novel Anabaseine-Derived Nicotinic Agents. 1994 , 206-211	:	2
39	Nicotinic Stimulation of Anterior Regional Cerebral Glucose Metabolism in Alzheimer Disease: Preliminary Study with Transdermal Patches. 1994 , 424-427	ć	3
38	Nicotine Effects on Memory Performance. 1995 , 329-335	:	2
37	Nicotinic Modulation of Cognitive Functioning in Humans. 1995, 345-351	:	1
36	Rationale and prospects for drugs that target nicotinic acetylcholine receptors. 2004 , 49-68	:	1
35	The Role of Nicotinic Acetylcholine Receptors in Cognitive Function. 2000, 587-602	.	7
34	Involvement of Neuronal Nicotinic Receptors in Disease. 2000 , 751-778	:	2
33	Clinical Aspects of Nicotinic Agents: Therapeutic Applications in Central Nervous System Disorders. 2000 , 779-812		9
32	Nicotine. 1996 , 271-314		4

(2008-2000)

31	Neurotrophic effects of central nicotinic receptor activation. 2000, 227-45	7
30	Perspectives in clinical Alzheimer's disease research and the development of antidementia drugs. 1998 , 53, 255-75	11
29	Neurotransmitters and cognition. 2006 , 98, 5-39	7
28	The neurobehavioral analysis of visuospatial attention in the rat. 2002 , 232-241	1
27	Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo. 2003 , 89, 2917-22	37
26	A pilot controlled clinical trial of ABT-418, a cholinergic agonist, in the treatment of adults with attention deficit hyperactivity disorder. 1999 , 156, 1931-7	146
25	Nicotine increases cerebellar activity during finger tapping. 2013 , 8, e84581	7
24	Nicotinic receptors in neurodegeneration. 2013 , 11, 298-314	73
23	Early Diagnosis and Treatment of Dementia Presenting as Transient Global Amnesia in a 76-Year-Old Man. 2004 , 6, 248-251	3
22	Transdermal Nicotine Patch Effects on EEG Power Spectra and Heart Rate Variability During Sleep of Healthy Male Adults. 2017 , 14, 499-505	4
21	Effects of a single transdermal nicotine dose on cognitive performance in adults with Down syndrome. 2001 , 237-45	2
20	Nicotine Effects on Attention Deficit Hyperactivity Disorder. 2001,	
19	Clinical Methodologies in the Examination of Nicotinic Effects on Cognition. 2001,	
18	Nicotine and Cognition in Young and Aged Nonhuman Primates. 2001,	
17	Neural Precursors as Preferential Targets for Drug Abuse: Long-Term Consequences and Latent Susceptibility to Central Nervous System Disorders. 2006 , 363-380	1
16	Pharmacodynamics. 2006 , 207-311	
15	Pharmacodynamics: Effects of Abused Drugs on Human Performance. 2007 , 65-95	
14	Cherry Tomatoes Ameliorate Scopolamine-induced Amnesia in Mice. 2008 , 13, 281-285	1

13	Attention Disturbances Associated with Neurological Disease. 2014 , 429-489	1
12	Nicotine, Catecholamines and Cognitive Enhancement. 1994 , 201-205	
11	Tobacco and the Body. 1995 , 55-70	
10	Possible Mechanisms Underlying Beneficial Effects of Nicotine on Cognitive Function. 1995 , 337-344	
9	The Action of Nicotine in the Mammalian Brain. 1999 , 223-236	
8	Pathological Mutations of Nicotinic Receptors and Nicotine-Based Therapies for Brain Disorders. <i>Research and Perspectives in Neurosciences</i> , 1999 , 1-15	
7	Cholinerge Behandlungsstrategien. 1999 , 179-190	1
6	The Role of Acetylcholine and Its Receptors in Retinal Processing. 2017,	
5	Attentional impairments to novel images in dementia. 2020 , 597-616	
4	Nicotine: abused substance and therapeutic agent. <i>Journal of Psychiatry and Neuroscience</i> , 1998 , 23, 95-1µ§	24
3	In Silico Analysis of Metabolites from Peruvian Native Plants as Potential Therapeutics against Alzheimer's Disease <i>Molecules</i> , 2022 , 27,	O
2	Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration <i>Degenerative Neurological and Neuromuscular Disease</i> , 5.4 2022 , 12, 31-59	O
1	Treatment of Alzheimer's Disease (With or Without Cerebrovascular Disease). 2003, 467-588	O